1. A Novel Continuous Powder Aerosolizer (CPA) for Inhalative Administration of Highly Concentrated Recombinant Surfactant Protein-C (rSP-C) Surfactant to Preterm Neonates
- Author
-
Windt Horst, Taut Friedemann, M Gama de Abreu, Koch Wolfgang, C De Muynck, Gerhard Pohlmann, Peter Iwatschenko, Markus Rast, and Publica
- Subjects
Pulmonary and Respiratory Medicine ,Recombinant surfactant protein C ,Chemistry, Pharmaceutical ,surfactant ,Pharmaceutical Science ,Endotracheal intubation ,powder ,complex mixtures ,infant respiratory distress syndrome ,Bolus (medicine) ,Pulmonary surfactant ,Administration, Inhalation ,Materials Testing ,Pulmonary medicine ,Humans ,Pharmacology (medical) ,Particle Size ,aerosolization ,Aerosolization ,Aerosols ,Respiratory Distress Syndrome, Newborn ,inhalation ,Chromatography ,Inhalation ,Chemistry ,Nebulizers and Vaporizers ,Infant, Newborn ,Humidity ,Pulmonary Surfactants ,Equipment Design ,respiratory system ,Pulmonary Surfactant-Associated Protein C ,Recombinant Proteins ,preterm neonate ,Anesthesia ,drug delivery ,Drug delivery ,dispersion ,Powders ,Infant, Premature - Abstract
Background: In pulmonary medicine, aerosolization of substances for continuous inhalation is confined to different classes of nebulizers with their inherent limitations. Among the unmet medical needs is the lack of an aerosolized surfactant preparation for inhalation by preterm neonates, to avoid the risks associated with endotracheal intubation and surfactant bolus instillation. In the present report, we describe a high-concentration continuous powder aerosolization system developed for delivery of inhalable surfactant to preterm neonates. Methods: The developed device uses a technique that allows efficient aerosolization of dry surfactant powder, generating a surfactant aerosol of high concentration. In a subsequent humidification step, the heated aerosol particles are covered with a surface layer of water. The wet surfactant aerosol is then delivered to the patient interface (e.g., nasal prongs) through a tube. Results: The performance characteristics of the system are given as mass concentration, dose rate, and size distribution of the generated aerosol. Continuous aerosol flows of about 0.84 L/min can be generated from dry recombinant surfactant protein-C surfactant, with concentrations of up to 12 g/m3 and median particle sizes of the humidified particles in the range of 3 to 3.5 µm at the patient interface. The system has been successfully used in preclinical studies. Conclusion: The device with its continuous high-concentration delivery is promising for noninvasive delivery of surfactant aerosol to neonates and has the potential for becoming a versatile disperser platform closing the gap between continuously operating nebulizers and discontinuously operating dry powder inhaler devices.
- Published
- 2013
- Full Text
- View/download PDF